[Hemolysis after combined azathioprine and allopurinol therapy].
In a 37 year old renal transplant woman haemolytic anaemia was observed in the course of a combined azathioprine-allopurinol therapy. Azathioprine is converted to 6-mercaptopurine, which then catalyzed by xanthine oxidase is oxidized to 6-thiouric acid. When allopurinol and azathioprine are administered simultaneously, high 6-mercaptopurine concentrations in plasma may be expected because of inhibition of xanthine oxidase activity by allopurinol. We assume that elevated plasma 6-mercaptopurine concentration could possibly be responsible for haemolytic anaemia in this renal transplant patient.
D000328:Adult; D000493:Allopurinol / Q000009:adverse effects* / Q000627:therapeutic use; D000743:Anemia, Hemolytic / Q000139:chemically induced*; D001379:Azathioprine / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D016030:Kidney Transplantation; D015122:Mercaptopurine / Q000097:blood; D014184:Transplantation, Homologous
D000493:Allopurinol; D015122:Mercaptopurine; D001379:Azathioprine
Hämolyse nach kombinierter Azathioprin-Allopurinol-Therapie.